Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects

Status Completed

Clinical Trial Summary

Clinical Trial Description

This is a Phase 1, Randomized, Open-Label, Three-Treatment, Three-Period Crossover Study to Assess Bioequivalence and Safety of TTYP01 Tablets to Radicava® Injection, and Radicava ORS® in Healthy Adult Subjects Under Fasting Conditions. The Primary objective is To characterize the bioequivalence of TTYP01 tablets (Test) and Radicava® injection (Reference 1) or Radicava ORS® (Reference 2) in healthy adult subjects under fasted conditions. The secondary objective is To determine the safety and tolerability of TTYP01 tablets (Test), Radicava Injection (Reference 1), and Radicava ORS (Reference 2) in healthy adult subjects under fasted conditions. In this open-label, randomized, 3-formulation, 3-period, crossover study, 30 healthy adult subjects will receive 1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T), or 1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes), or 1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2) after an overnight fast in each period according to the randomization sequence. Subjects will be randomized to 1 of 6 parallel sequences (5 subjects per sequence), with a washout period of at least 96 hours between the periods. The approximate study period is 6 weeks, including screening and follow-up. ;

Study Design

Related Conditions & MeSH terms

Healthy Adult Subjects

Clinical Trial Details

NCT number	NCT06107205
Study type	Interventional
Source	Auzone Biological Technology Pty Ltd
Contact
Status	Completed
Phase	Phase 1
Start date	November 7, 2023
Completion date	December 14, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03267732` - A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)	Phase 1
Completed	`NCT05040113` - A Study On Human Mass Balance And Biotransformation	Phase 1
Completed	`NCT01433835` - Safety and Pharmacokinetics of Single Oral Doses of MBX-400 in Healthy Volunteers	Phase 1
Completed	`NCT04029090` - A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects	Phase 1
Completed	`NCT04586985` - Safety, Tolerability and Pharmacokinetics of FTX-6058	Phase 1
Completed	`NCT04481789` - Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)	Phase 1
Completed	`NCT04629131` - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy Adults	Phase 1
Recruiting	`NCT06063291` - Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects	Phase 1
Completed	`NCT04203862` - A Study of NPC-22 in Healthy Adult Males	Phase 1
Recruiting	`NCT05641181` - A Trial of CRB4101 in Healthy Subjects	Phase 1
Completed	`NCT04521192` - Bioequivalence of Fluzoparib(SHR3162) Study on Healthy Chinese Adult Subjects	Phase 1
Completed	`NCT04400123` - A Bioequivalence Study of Famitinib Malate on Healthy Chinese Volunteers	Phase 1
Completed	`NCT04811469` - Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults	Phase 1
Completed	`NCT04291846` - A Food Effect Study of SHR1459 on Healthy Chinese Adult Subjects	Phase 1
Completed	`NCT01364441` - Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects	Phase 1
Completed	`NCT02691702` - Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers	Phase 1
Recruiting	`NCT05334043` - Pharmacokinetics and Bioavailability of Curcumin UP 30 Capsules in Healthy Adult Subjects	Phase 1
Completed	`NCT04493281` - Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects	Phase 1
Completed	`NCT01376063` - Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects	Phase 1
Completed	`NCT04481750` - Study of Oral Edaravone in Healthy Adult Males	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.